In patients treated with SRLs before surgery, the number of tumor infiltrating CD8+ and CD138+ lymphocytes, CD68+ macrophages, and the CD68+/CD8+ ratio did not differ among invasive and non‐invasive tumors. This evidence concerns the gene CD68 and neoplasm.